Unlike Pfizer's mRNA vaccine, BriLife is a self-propagating, live-virus vaccine
Israel's Defense Ministry announced on Sunday it sent a shipment of 1,000 vials of the Israel-developed BriLife coronavirus vaccine to Georgia, US, where the second phase of its clinical trials is taking place.
BriLife is a self-propagating, live-virus vaccine, which sets it apart from mRNA vaccines produced by companies like Pfizer, which are currently being used in Israel's vaccination campaign. It is delivered via injection.
The vaccine was developed by the Israel Institute for Biological Research and its trials and distribution internationally is handled by the US company NRx Pharmaceuticals. It has successfully passed its first phase trials in Israel.
None of the vaccines authorized for use in the United States contain a live virus, according to the Centers for Disease Control.
According to NRx chair Prof. Jonathan Javitt, the third phase of the clinical trial is likely to start in October.
NRx said the Israeli research institute will provide technical assistance while receiving royalty and milestone payments for its intellectual property. It also said it has committed to supplying all required doses of the vaccine for the population of Israel.